Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?

Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23.

Authors

Daniel M Geynisman¹, Eric A Ross², Elizabeth R Plimack³

Affiliations

¹ Medical Oncology, Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA.
² Department of Biostatistics Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA.
³ Medical Oncology, Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA. Electronic address: [email protected].

PMID: 26116295
DOI: 10.1016/j.eururo.2015.06.009

No abstract available

Publication types

Editorial
Comment

MeSH terms

Abiraterone Acetate / therapeutic use*
Antineoplastic Agents, Hormonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Density Conservation Agents / therapeutic use*
Bone Neoplasms / drug therapy*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Steroid Synthesis Inhibitors / therapeutic use*

Substances

Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Steroid Synthesis Inhibitors
Abiraterone Acetate